Klinik und Poliklinik für Urologie und Kinderurologie
Klinikum / Johannes Gutenberg-Universität Mainz
Forschungsprojekte
Ergebnisse pro Seite:
25
2020 - 2022
Outcome of transperitoneal versus retroperitoneal robot assisted partial nephrectomy (TRAREN trial)- PD Dr. ReneMager
2020 - 2022
Comparative assessment of multi-tract versus single-tract percutaneous nephrolithotomy- PD Dr. ReneMager
2020 - 2022
The impact of artesunate on the matastatic behaviour of parental and cisplatin-resistant bladder cancer cells- PD Dr. Dr. EvaJüngel
2020 - 2022
Shikonin, a new compound to combate the growth of therapy-resistant renal cell carcinoma?- PD Dr. Dr. EvaJuengel
2020 - 2022
Evaluation the antitumoral efficacy of Shikonin on the mestastatic spread of therapy-resistant renal cell carcinoma in vitro- PD Dr. Dr. EvaJüngel
2019 - 2025
BMS CA17-078: A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle Invasive Bladder Cancer- Prof. Dr. IgorTsaur,
- PD Dr. ThomasHöfner,
- PD Dr. WolfgangJäger
2019 - 2021
Does artesunate induce cell death in docetaxel-resistant prostate carcinoma?- PD Dr. Dr. EvaJüngel
2019 - 2021
Artesunates impact on the progressive growth behavior of therapy-sensitive and cisplatin-resistant bladder cancer cells- PD Dr. Dr. EvaJüngel
2018 - 2021
The impact of artesunate on docetaxel-resistant prostate carcinoma in vitro- PD Dr. EvaJüngel
2018 - 2020
Prospective Registry for Patients Undergoing Surgery for Male Stress Urinary Incontinence in Multiple European Centres (SATURN)- RizwanHamid,
- Dr. TanjaHüsch
2018 - 2020
Comparison between artificial urinary sphincter and adjustable male sling in the treatment of moderate male urinary stress incontinence (AUSTIN)- Univ.-Prof. Dr. AxelHaferkamp,
- Dr. AxelKretschmer,
- Dr. MartinKurosch
2018 - 2020
INCB 54828-201: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations- Prof. Dr. IgorTsaur,
- PD Dr. ThomasHöfner,
- PD Dr. WolfgangJäger
2018 - 2019
FORT-1:Phase 2/3 study of rogaratinib (BAY 1163877) vs chemotherapy in patients with FGFR-positive locally advanced or metastatic urothelial carcinoma- Prof. Dr. GeorgBartsch,
- Prof. Dr. IgorTsaur,
- PD Dr. ThomasHöfner
2018 - 2022
FORT-2: Phase 1b/2 study of rogaratinib (BAY 1163877) in combination with atezolizumab in urothelial carcinoma- Prof. Dr. GeorgBartsch,
- Prof. Dr. IgorTsaur,
- PD Dr. ThomasHöfner